TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06129864: A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, W

Sponsor: AstraZeneca · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1145 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT06129864 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06129864 Rescue Dossier →